# NCT03775265 (NCT03775265)

> Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03775265
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: National Cancer Institute (NCI)
- Conditions: Bladder Urothelial Carcinoma; Muscle Invasive Bladder Carcinoma; Stage II Bladder Cancer AJCC v8; Stage IIIA Bladder Cancer AJCC v8
- Interventions: Atezolizumab; Biopsy of Bladder; Cisplatin; Computed Tomography; Cystoscopy; Fluorouracil; Gemcitabine; Magnetic Resonance Imaging; Mitomycin; Quality-of-Life Assessment; Radiation Therapy; Survey Administration; Transurethral Resection of Bladder Tumor
- Enrollment: 475
- Primary outcome: Bladder intact event-free survival (BI-EFS)

## Commentary we found

- X threads: 13
- YouTube: 3
- Podcasts: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=nct03775265

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03775265", "email": "<work email>"}; the inbox owner confirms by the emailed link.